Oral Herpes Clinical Trials

Find Oral Herpes Clinical Trials Near You

An Open-label Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of VG2025 in the Treatment of Advanced Intrahepatic Cholangiocarcinoma

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. Currently, one phase I dose escalation safety study has been completed in China and the United States respectively, both demonstrating excellent safety profiles with no dose-limiting toxicities (DLTs) observed and no maximum tolerated dose (MTD) identified. Moreover, it has shown preliminary efficacy in treating advanced tumors. Considering the actual clinical needs and the volume of intratumoral administration, a more appropriate recommended phase 2 dose (RP2D) level has been selected for the phase II clinical trial.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Signed written informed consent form.

• Age 18 to 75 years (inclusive), male or female.

• Histologically or cytologically confirmed advanced intrahepatic cholangiocarcinoma.

• Eligible participants of childbearing participants(male and female) must agree to use a reliable method of contraception during the trial and for at least 90 days after dosing; females of childbearing potential must have a negative blood pregnancy test 7 days before enrollment.

Locations
Other Locations
China
The First Affiliated Hospital,Zhejiang University School of Medicine
RECRUITING
Hangzhou
Contact Information
Primary
Yinan Shen
fysyn@163.com
+86-0571-87236666
Time Frame
Start Date: 2026-08-25
Estimated Completion Date: 2028-11-13
Participants
Target number of participants: 30
Treatments
Experimental: Single Arm
VG2025 (Recommended Phase II Dose), Intratumoral Injection, Q4W
Sponsors
Leads: Virogin Biotech Ltd.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials